PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England ...

Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment between 2015 ...

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Experts discuss the current status of neoadjuvant ADC therapies, eligibility criteria, and future treatment pathways for high-risk patients.

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic ...

—There was no significant difference in invasive disease-free survival between patients with human epidermal growth factor receptor 2-positive (HER2+) T1micN0 breast cancer who were and were not ...